Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment
Oncogenic mutations in KRAS drive common metabolic programmes that facilitate tumour
survival, growth and immune evasion in colorectal carcinoma, non-small-cell lung cancer …
survival, growth and immune evasion in colorectal carcinoma, non-small-cell lung cancer …
[HTML][HTML] Metabolic pathways regulating colorectal cancer initiation and progression
S La Vecchia, C Sebastián - Seminars in cell & developmental biology, 2020 - Elsevier
Colorectal cancer (CRC) is one of the most common types of cancer worldwide. Despite
recent advances in the molecular genetics of CRC, poor treatment outcomes highlight the …
recent advances in the molecular genetics of CRC, poor treatment outcomes highlight the …
Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH
More than half of human colorectal cancers (CRCs) carry either KRAS or BRAF mutations
and are often refractory to approved targeted therapies. We found that cultured human CRC …
and are often refractory to approved targeted therapies. We found that cultured human CRC …
Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?
Objectives To investigate whether CT-based radiomics signature can predict
KRAS/NRAS/BRAF mutations in colorectal cancer (CRC). Methods This retrospective study …
KRAS/NRAS/BRAF mutations in colorectal cancer (CRC). Methods This retrospective study …
Associations between somatic mutations and metabolic imaging phenotypes in non–small cell lung cancer
PET-based radiomics have been used to noninvasively quantify the metabolic tumor
phenotypes; however, little is known about the relationship between these phenotypes and …
phenotypes; however, little is known about the relationship between these phenotypes and …
Targeting KRAS: the elephant in the room of epithelial cancers
V Merz, M Gaule, C Zecchetto, A Cavaliere… - Frontiers in …, 2021 - frontiersin.org
Mutations of the proto-oncogene KRAS are the most frequent gain-of-function alterations
found in cancer. KRAS is mutated in about 30% of all human tumors, but it could reach more …
found in cancer. KRAS is mutated in about 30% of all human tumors, but it could reach more …
Targeting metabolic reprogramming in KRAS-driven cancers
K Kawada, K Toda, Y Sakai - International journal of clinical oncology, 2017 - Springer
Mutations of KRAS are found in a variety of human malignancies, including in pancreatic
cancer, colorectal cancer, and non-small cell lung cancer at high frequency. To date, no …
cancer, colorectal cancer, and non-small cell lung cancer at high frequency. To date, no …
Radiomics in oncological PET/CT: clinical applications
JW Lee, SM Lee - Nuclear medicine and molecular imaging, 2018 - Springer
Abstract 18 F–fluorodeoxyglucose (FDG) positron emission tomography/computed
tomography (PET/CT) is widely used for staging, evaluating treatment response, and …
tomography (PET/CT) is widely used for staging, evaluating treatment response, and …
[HTML][HTML] Metabolic alterations caused by KRAS mutations in colorectal cancer contribute to cell adaptation to glutamine depletion by upregulation of asparagine …
K Toda, K Kawada, M Iwamoto, S Inamoto, T Sasazuki… - Neoplasia, 2016 - Elsevier
A number of clinical trials have shown that KRAS mutations of colorectal cancer (CRC) can
predict a lack of responses to anti-epidermal growth factor receptor–based therapy …
predict a lack of responses to anti-epidermal growth factor receptor–based therapy …
Imaging genomics in cancer research: limitations and promises
HX Bai, AM Lee, L Yang, P Zhang… - The British journal of …, 2016 - academic.oup.com
Recently, radiogenomics or imaging genomics has emerged as a novel high-throughput
method of associating imaging features with genomic data. Radiogenomics has the potential …
method of associating imaging features with genomic data. Radiogenomics has the potential …